AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Cassava Sciences Boosts Medical Leadership with New CMO Appointment, Analysts Maintain Cautionary Price Target
ByAinvest
Thursday, Aug 7, 2025 2:39 pm ET1min read
Cassava Sciences has appointed Joseph Hulihan as Chief Medical Officer, boosting its leadership team. Analysts have set a consistent one-year price target of $2.00, representing a 14.53% potential downside from the current trading price. Current recommendations suggest holding, reflecting cautious optimism. Hulihan brings expertise from Marinus Pharmaceuticals and Janssen Pharmaceutical Companies, focusing on simufilam for addressing Tuberous Sclerosis Complex-related epilepsy.
Cassava Sciences, Inc. (SAVA) has appointed Joseph Hulihan as its new Chief Medical Officer (CMO), bolstering its leadership team. Hulihan will devote approximately half of his professional time to Cassava, advising on the clinical development of simufilam, an investigational candidate for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy [1].Hulihan brings extensive experience in the development of therapeutics for neurological disorders. He previously served as CMO at Marinus Pharmaceuticals and held senior leadership roles in Medical Affairs at Janssen Pharmaceutical Companies of Johnson & Johnson. Prior to joining Cassava, Hulihan focused on the development of ganaxolone for seizure disorders including TSC-related epilepsy at Marinus, which was acquired by Immedica Pharma in March 2025 [1].
Analysts have set a consistent one-year price target of $2.00 for Cassava Sciences, representing a 14.53% potential downside from the current trading price. Current recommendations suggest holding, reflecting cautious optimism [1].
Hulihan's appointment coincides with positive preclinical results for simufilam. A study conducted in collaboration with the TSC Alliance using a well-accepted Tsc1-knockout mouse model demonstrated simufilam’s anti-seizure activity [2]. The first clinical study for simufilam in TSC-related epilepsy is expected to begin in H1 2026.
References:
[1] https://www.nasdaq.com/articles/cassava-sciences-appoints-joseph-hulihan-new-chief-medical-officer
[2] https://www.cassavasciences.com/news-releases/news-release-details/cassava-sciences-reports-positive-preclinical-study-evaluating
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet